Know Stroke Podcast: UC's Mistry discusses recent, upcoming research

The University of Cincinnati's Eva Mistry, MBBS, was a recent guest on the Know Stroke Podcast and the Recovery After Stroke Podcast.

She discussed a new study with $9.6 million funding support from the Patient-Centered Outcomes Research Institute (PCORI) that will examine the effectiveness of a stroke treatment for patients with a pre-stroke disability, one of the first studies to focus on this population. Mistry is principal investigator of the study.

Current guidelines for endovascular treatment, an acute stroke treatment where a catheter is used to remove large blood clots from the brain, exclude patients with prestroke disability because they were not included in the clinical trials for the procedure, Mistry noted.

"The question [of the trial] is fairly simple, but the overarching goal which I hope we will be able to do is with this data we’ll be able to arm researchers in the future to not reflexively say that because we’re doing this novel stroke intervention study, we’re going to exclude patients with disabilities," said Mistry, assistant professor in the Department of Neurology and Rehabilitation medicine in UC’s College of Medicine and a UC Health physician at the UC Gardner Neuroscience Institute.

Mistry also talked with the podcast hosts about the success and future of mobile stroke units, the results of the BEST-II trial she led and presented at the International Stroke Conference last month and what she would do if she had a "magic wand" to change one aspect of clinical stroke research. 

Listen to the Know Stroke Podcast episode.

Listen or watch the Recovery After Stroke Podcast episode.

Read more about the BEST-II trial results.

Read more about Mistry's study with funding support from PCORI.

Featured photo at top of Dr. Mistry with a patient. Photo/Andrew Higley/UC Marketing + Brand.

Related Stories


WLWT: UC hosts RESET epilepsy trial

May 3, 2023

WLWT spoke with the University of Cincinnati's Brandon Foreman about a clinical trial testing a new treatment for status epilepticus, the most severe and deadly form of epilepsy.